Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ardea Biosciences, Inc.
San Diego, California, United Statesardeabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ardea Biosciences developed lesinurad (RDEA594), a selective URAT1 inhibitor for gout treatment that reached Phase 3 clinical trials. In Phase 2 trials, lesinurad showed response rates between 70-80% compared to 28% for placebo.
- Therapeutic areas
- Metabolic DisordersRheumatologyImmunologyOncologyInfectious Diseases
- Modalities
- small molecules
- Industry
- Biotech
02
Partnerships
Bayer HealthCare (for BAY 86-9766/RDEA119)
Beyond the preview
Go deeper on Ardea Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ardea Biosciences, Inc..